Phase 2 study of irinotecan plus cetuximab rechallenge as third-line treatment in KRAS wild-type metastatic colorectal cancer: JACCRO CC-08

Background Regorafenib or trifluridine/tipiracil as third-line treatment have limited efficacy in metastatic colorectal cancer (mCRC). Methods This Phase 2 trial evaluated the efficacy and safety of irinotecan plus cetuximab rechallenge as third-line treatment in KRAS wild-type mCRC patients who ach...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	British journal of cancer Jg. 123; H. 10; S. 1490 - 1495
Hauptverfasser:	Masuishi, Toshiki, Tsuji, Akihito, Kotaka, Masahito, Nakamura, Masato, Kochi, Mitsugu, Takagane, Akinori, Shimada, Ken, Denda, Tadamichi, Segawa, Yoshihiko, Tanioka, Hiroaki, Hara, Hiroki, Sagawa, Tamotsu, Watanabe, Takanori, Takahashi, Takao, Negoro, Yuji, Manaka, Dai, Fujita, Hideto, Suto, Takeshi, Takeuchi, Masahiro, Ichikawa, Wataru, Fujii, Masashi
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	London Nature Publishing Group UK 10.11.2020 Nature Publishing Group
Schlagworte:	631/67/1059/602 631/67/1504/1885 Adenocarcinoma - drug therapy Adenocarcinoma - genetics Adenocarcinoma - mortality Adenocarcinoma - pathology Adult Aged Aged, 80 and over Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biomedical and Life Sciences Biomedicine Cancer Research Cetuximab - administration & dosage Cetuximab - adverse effects Chemotherapy, Adjuvant Colorectal cancer Colorectal carcinoma Colorectal Neoplasms - drug therapy Colorectal Neoplasms - genetics Colorectal Neoplasms - mortality Colorectal Neoplasms - pathology Disease control Drug Resistance Epidemiology Female Humans Immunotherapy Inhibitor drugs Irinotecan Irinotecan - administration & dosage Irinotecan - adverse effects K-Ras protein Male Metastases Metastasis Middle Aged Molecular Medicine Monoclonal antibodies Neoplasm Metastasis Oncology Patients Proto-Oncogene Proteins p21(ras) - genetics Salvage Therapy Survival Survival Analysis Targeted cancer therapy Treatment Outcome
ISSN:	0007-0920, 1532-1827, 1532-1827
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!